Patient	Age	Gender	Race	Ethnicity	ECOG	Stage	BRAF
M10101	66	Female	White	Non-Hispanic	2	III	WT
M10103	70	Female	White	Non-Hispanic	1	III	K601N
M10104	60	Male	White	Non-Hispanic	1	IV	V600E
M10105	73	Male	White	Non-Hispanic	0	IV	WT
M10106	66	Male	White	Non-Hispanic	0	IV	WT
M10107	71	Male	White	Non-Hispanic	0	III	WT
M10108	85	Female	White	Non-Hispanic	1	III	WT

Supplemental Table 1a: Demographics of the patient population eligible for the trial.

Total (n = 7)	RELATED		UNRELATED				
AE Preferred Term	Grade	Grade	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
M10101							
Flatulence	0	0	1	0	0	0	0
Hypertension	0	0	0	1	1	0	0
Pneumatosis	0	0	0	0	1	0	0
M10103							
Injection site reaction							
Erythema w/ Pruritis	0	1	0	0	0	0	0
Erythema/Pain	1	0	0	0	0	0	0
M10104							
Injection site reaction							
Erythema	1	0	0	0	0	0	0
Lymphocyte count decreased	1	0	0	0	0	0	0
Lymphoedema	0	0	1	0	0	0	0
M10105							
Back pain	1	0	0	0	0	0	0
Clostridial sepsis	0	0	0	0	0	0	1
Constipation	0	0	0	1	0	0	0
Decreased appetite	0	0	1	0	0	0	0
Dry mouth	0	0	1	0	0	0	0
Injection site reaction							
Erythema	1	0	0	0	0	0	0
Pruritus	1	0	0	0	0	0	0
Insomnia	0	0	1	0	0	0	0
Multiple organ dysfunction syndrome	0	0	0	0	0	1	0
Muscle spasms	0	0	1	0	0	0	0
M10106							
Injection site reaction	1	0	0	0	0	0	0
Erythema							
M10107							
Constipation	0	0	0	1	0	0	0
Diverticulitis	0	0	0	1	0	0	0
Fatigue	0	0	1	0	0	0	0
Injection site reaction							
Site reaction	1	0	0	0	0	0	0
Hypo aesthesia	1	0	0	0	0	0	0
Insomnia	0	0	1	0	0	0	0
Pruritus	1	0	0	0	0	0	0
Tumor hemorrhage	1	0	0	0	0	0	0
M10108							
Injection site reaction							
Erythema	1	0	0	0	0	0	0
Tumor Hemorrhage	2	0	0	0	0	0	0
Tumor Pain	0	2	0	0	0	0	0

Supplemental Table 1b: Related and unrelated adverse events to IFx-Hu2.0